Live Breaking News & Updates on Bernd jilma

Stay informed with the latest breaking news from Bernd jilma on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Bernd jilma and stay connected to the pulse of your community

Bio&Bio's toxic shock syndrome vaccine research concluded

Positive results showed the TSST-1 vaccine is effective with immunisation lasting for at least two years - News - PharmaTimes

Bernd-jilma , Andreas-roetzer , Bio , Meduni-vienna-department-of-clinical-pharmacology , Meduni-vienna , Clinical-pharmacology , Bio-amp- , Accine- , Oxic-shock-syndrome ,

COVID-19 Collection

COVID-19 Collection
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.

United-states , India , United-kingdom , Brazil , Madrid , Spain , China , Wuhan , Hubei , Fen-zhou , Shanxi , France

New therapeutic approach discovered for reducing the risk of thrombosis

E-Mail
IMAGE: First authors Taras Afonyushkin (left) and Georg Obermayer (right) with Last author Christoph Binder (middle)
view more
Credit: Laura Alvarez/CeMM
Thrombotic occlusion of blood vessels, which leads to myocardial infarctions, strokes and venous thromboembolisms, is the major cause of death in the western hemisphere. Therefore, it is of critical importance to understand mechanisms preventing thrombus formation. A new study by the research group of Christoph Binder, Principal Investigator at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences and Professor at the Medical University of Vienna, now explains the important role of immunoglobulin-M (IgM) antibodies in preventing thrombosis. The study published in the journal

Germany , California , United-states , San-diego , Austria , Vienna , Wien , Austrian , Christoph-binder , Georg-obermayer , Bernd-jilma , Waltraud-schrottmaier

PRESS RELEASE : Apogenix AG: COVID-19 targeted treatment trial launched in Vienna

PRESS RELEASE : Apogenix AG: COVID-19 targeted treatment trial launched in Vienna
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Germany , Heidelberg , Baden-wuberg , Vienna , Wien , Austria , Russia , Spain , Michael-bergmann , Bernd-jilma , Apogenix , Henning-walczak

Apogenix AG: COVID-19 targeted treatment trial launched in Vienna

DGAP-News: Apogenix AG
/ Key word(s): Study
22.12.2020 / 10:00
COVID-19: targeted treatment trial launched in Vienna
(Vienna/Heidelberg/Cologne/London, 22 December 2020) A phase II clinical trial of a treatment for COVID-19 patients is currently starting at the Medical University of Vienna as a sub-study of the Austrian CoronaVirus Adaptive Clinical Trial (ACOVACT). The trial was initiated as an academia-industry collaboration (investigator Initiated trial) between Apogenix AG, a biotech company based in Heidelberg, and their scientific consultant Henning Walczak and his teams at the University of Cologne and University College London (UCL).
Patients with severe to critical COVID-19 are now being treated with an immunotherapeutic drug, the Fas ligand blocker asunercept, from Apogenix within the framework of the Austrian CoronaVirus Adaptive Clinical Trial (ACOVACT). ACOVACT is a randomised, controlled, multi-centre, open-label clinical trial sponsored by MedUni Vienna. Within ACOVACT, different treatments for COVID-19 are compared to one another.

Germany , Heidelberg , Baden-wuberg , Vienna , Wien , Austria , Russia , Spain , Johannes-angerer , Michael-bergmann , Bernd-jilma , Katja-arnold